Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?

MLA

Lazar-Poloczek, Elżbieta, et al. “Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?” Biomedicines, vol. 10, no. 11, Nov. 2022. EBSCOhost, https://doi.org/10.3390/biomedicines10112959.

APA

Lazar-Poloczek, E., Romuk, E., Jacheć, W., Stanek, W., Stanek, B., Szołtysik, M., Techmański, T., Hasterok, M., & Wojciechowska, C. (2022). Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI? Biomedicines, 10(11). https://doi.org/10.3390/biomedicines10112959

Chicago

Lazar-Poloczek, Elżbieta, Ewa Romuk, Wojciech Jacheć, Wiktoria Stanek, Bartosz Stanek, Monika Szołtysik, Tomasz Techmański, Maja Hasterok, and Celina Wojciechowska. 2022. “Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?” Biomedicines 10 (11). doi:10.3390/biomedicines10112959.